Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
Status:
Recruiting
Trial end date:
2022-04-26
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety,
tolerability, pharmacokinetics and anti-tumor activity of LDP in subjects with advanced
malignant tumors.